This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Up 5.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stock Market News for Nov 02, 2023
by Zacks Equity Research
Wall Street closed higher on Wednesday after the Federal Reserve kept its interest rates unchanged.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 10.02% and 5.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
3D Systems (DDD) Report Preliminary 3Q Results, Scrap 2023 View
by Zacks Equity Research
3D Systems (DDD) expects to report dismal third-quarter 2023 results due to softness in printer demand.
ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.
3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity
by Zacks Equity Research
3D Systems' (DDD) collaboration with Klarity is likely to help it in expanding the distribution of its FDA-approved VSP Bolus solution.
Should You Invest in the Invesco Biotechnology & Genome (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 18.82% and 12.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings
by Zacks Equity Research
The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
United Therapeutics (UTHR) Q1 Earnings Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?